Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/2/194 |
| _version_ | 1828146974932598784 |
|---|---|
| author | Gils Roex Tom Feys Yves Beguin Tessa Kerre Xavier Poiré Philippe Lewalle Peter Vandenberghe Dominique Bron Sébastien Anguille |
| author_facet | Gils Roex Tom Feys Yves Beguin Tessa Kerre Xavier Poiré Philippe Lewalle Peter Vandenberghe Dominique Bron Sébastien Anguille |
| author_sort | Gils Roex |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively. |
| first_indexed | 2024-04-11T20:53:51Z |
| format | Article |
| id | doaj.art-86efcb9c5e2f4835884c8341b7c9f981 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-11T20:53:51Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-86efcb9c5e2f4835884c8341b7c9f9812022-12-22T04:03:45ZengMDPI AGPharmaceutics1999-49232020-02-0112219410.3390/pharmaceutics12020194pharmaceutics12020194Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial DataGils Roex0Tom Feys1Yves Beguin2Tessa Kerre3Xavier Poiré4Philippe Lewalle5Peter Vandenberghe6Dominique Bron7Sébastien Anguille8Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, BelgiumAriez International BV, 9000 Ghent, BelgiumDepartment of Hematology, University of Liège, 4000 Liège, BelgiumDepartment of Hematology, University Hospital Ghent, 9000 Ghent, BelgiumFaculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, BelgiumDepartment of Hematology, Institut Jules Bordet, 1000 Brussels, BelgiumDepartment of Hematology, University Hospitals Leuven, 3000 Leuven, BelgiumDepartment of Hematology, Institut Jules Bordet, 1000 Brussels, BelgiumTumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, BelgiumChimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.https://www.mdpi.com/1999-4923/12/2/194car-t cellsimmunotherapyb-cell malignanciescd19bcma |
| spellingShingle | Gils Roex Tom Feys Yves Beguin Tessa Kerre Xavier Poiré Philippe Lewalle Peter Vandenberghe Dominique Bron Sébastien Anguille Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data Pharmaceutics car-t cells immunotherapy b-cell malignancies cd19 bcma |
| title | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| title_full | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| title_fullStr | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| title_full_unstemmed | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| title_short | Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data |
| title_sort | chimeric antigen receptor t cell therapy for b cell hematological malignancies an update of the pivotal clinical trial data |
| topic | car-t cells immunotherapy b-cell malignancies cd19 bcma |
| url | https://www.mdpi.com/1999-4923/12/2/194 |
| work_keys_str_mv | AT gilsroex chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT tomfeys chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT yvesbeguin chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT tessakerre chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT xavierpoire chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT philippelewalle chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT petervandenberghe chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT dominiquebron chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata AT sebastienanguille chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata |